Change at the 最高の，を越す for Biogen after Alzheimer's 麻薬 flops
Biogen will 取って代わる its CEO and 大部分は abandon marketing of its 議論の的になる Alzheimer's 麻薬 Aduhelm いっそう少なく than a year after the 医薬's 開始する，打ち上げる 誘発する／引き起こすd a （激しい）反発 from 専門家s, doctors and 保険会社s.
CEO Michel Vounatsos will continue to lead the Biogen until a 後継者 is 設立する, the company 発表するd Tuesday. Vounatsos joined the company in 2016 and was the 長，指導者 architect of Biogen's 戦略 built around Aduhelm.
For now, Biogen said it is "大幅に 除去するing" spending on Aduhelm as part of a $1 billion dollar cost-saving 計画（する） designed to refocus the company's flagging biotech 商売／仕事.
The 告示 代表するs a stark 承認 that the Cambridge, Massachusetts-based company has failed to find a market for a 麻薬 that was 推定する／予想するd to 運動 its 商売／仕事 for years to come.
Aduhelm was the first new Alzheimer´s 麻薬 introduction in nearly two １０年間s. 最初 定価つきの at $56,000 a year, 分析家s 予報するd it would quickly become a blockbuster 麻薬 that would 生成する billions for Biogen.
But doctors have been hesitant to 定める／命ずる it, given weak 証拠 that the 麻薬 slows the progression of Alzheimer´s. 保険会社s have 封鎖するd or 制限するd ニュース報道 over the 麻薬´s high price tag and uncertain 利益. Even the company's 決定／判定勝ち（する） to 削除する the 麻薬's price in half- to $28,000 a year - did little to 改善する uptake.
The Biogen Inc., （警察，軍隊などの）本部, March 11, 2020, in Cambridge, 集まり. Biogen is looking for a new CEO, いっそう少なく than a year after its 開始する，打ち上げる of its Alzheimer's 麻薬 Aduhelm 大部分は fizzled. The company said Tuesday, May 3, 2022 that 現在の CEO Michel Vounatsos will continue to lead the company until his 後継者 is 任命するd. (AP Photo/Steven Senne, とじ込み／提出する)
The biggest 後退 （機の）カム last month when the 連邦の 政府's Medicare health 計画（する） 課すd strict 限界s on who can get the 麻薬, wiping out most of its 可能性のある U.S. market. The 広大な 大多数 of U.S. Alzheimer´s 患者s are old enough to qualify for Medicare, which covers more than 60 million people, 含むing those 65 and older.
The infused 麻薬 brought in just $2.8 million in sales in the first ４半期/4分の1, which ended March 31.
Biogen said Tuesday that it 調書をとる／予約するd about $275 million in 告発（する），告訴（する）／料金s from Aduhelm 在庫 令状-offs in the ４半期/4分の1, and it would essentially shutdown its sales and marketing 組織／基盤／下部構造 supporting the 麻薬.
Aduhelm expenses dragged 負かす／撃墜する the company's 年４回の results and Biogen fell short of 塀で囲む Street 発射／推定s, 報告（する）／憶測ing adjusted 逮捕する income of $535 million, or $3.62 per 株. 分析家s 予測（する） 収入s of $4.34 per 株, によれば FactSet.
Biogen (n)役員／(a)執行力のあるs said the 制限する ive Medicare 決定／判定勝ち（する） essentially 否定するd Aduhelm to most 適格の U.S. 患者s. Last month the company 発表するd it was pulling its marketing 使用／適用 for the 麻薬 in Europe.
Biogen will continue running a federally-委任統治（領）d confirmatory 裁判，公判 designed to 設立する if the 麻薬 truly slows Alzheimer's.
The drugmaker's 年４回の 歳入 fell 6% to $2.5 billion, 圧力d by lower sales of 多重の sclerosis 麻薬s in the U.S. 予定 to cheaper, generic 競争. The company also 報告（する）／憶測d lower sales of its specialty 麻薬 Spinraza, which is used to 扱う／治療する a rare spinal disorder in children.
For the year, Biogen 再確認するd 収入s 指導／手引 of between $14.25 and $16.00 per 株.
Biogen (n)役員／(a)執行力のあるs said they will continue 追求するing new Alzheimer´s 治療s 含むing a 麻薬 類似の to Aduhelm. 研究員s are を待つing last-行う／開催する／段階 実験（する）ing results for the 麻薬 in the 落ちる. But the company also 最高潮の場面d other 麻薬s in its pipeline, 含むing 可能性のある 治療s for 不景気 and schizophrenia.
Vounatsos 出発 was 推定する／予想するd "given the many 後退s the company has 直面するd," RBC 資本／首都 Markets 分析家 Brian Abrahams wrote Tuesday. The move and 再組織 "will be 井戸／弁護士席 received over the long 称する，呼ぶ／期間／用語, and give the company a fresh start in refocusing R&D 優先s."
株 of Biogen Inc. rose いっそう少なく than 1%.
